iGii spotlights carbon electrode platform at ADLM 2026
Bottom line
iGii is using ADLM 2026 to make a broader pitch to diagnostics developers: electrode materials may be becoming a bottleneck for the next wave of point-of-care testing, including veterinary applications. In a Newswise announcement tied to the July 28-30 meeting in Anaheim, the advanced materials company said it would exhibit its proprietary carbon nanomaterial, Gii, alongside Gii-Sens Research electrodes and a microheater platform aimed at molecular diagnostics, immunoassays, electrochemical biosensing, and veterinary diagnostics. On its website, iGii says Gii-Sens is designed for point-of-care use, built as a pure porous 3D carbon nanostructure without inks or binders, and intended to improve sensitivity, stability, reproducibility, and performance in complex sample types such as blood, urine, and milk. (newswise.com)
Why it matters: For veterinary professionals, this is less about one company’s trade show booth and more about where diagnostic platform development may be heading. Carbon-based electrochemical biosensors are attracting attention because they can support rapid, lower-cost testing closer to the patient, and published reviews suggest their material properties may help with stability, miniaturization, and translation into decentralized care settings. In veterinary medicine, that could eventually support faster in-clinic or on-farm assays for infectious disease, metabolic monitoring, and other use cases where turnaround time shapes treatment and biosecurity decisions. (pubs.rsc.org)
What to watch: Watch for evidence that iGii’s platform moves from materials claims into named veterinary diagnostic partnerships, validation data, and commercial product launches after ADLM 2026. (newswise.com)
iGii’s ADLM 2026 exhibit is built around a familiar problem in diagnostics: promising assays often depend on legacy electrode materials that can be expensive, difficult to scale, or less reliable in real-world sample matrices. In its event announcement, the company said it would use the July 28-30 ADLM meeting in Anaheim to showcase Gii, its proprietary carbon nanomaterial, as well as Gii-Sens Research electrodes and a microheater technology platform for next-generation diagnostics, with veterinary diagnostics listed among its target markets. (newswise.com)
That message lands at a time when diagnostics developers are under pressure to move more testing out of centralized labs and into clinics, homes, and field settings. A 2023 review in Sensors & Diagnostics described carbon-based electrochemical biosensors as promising tools for rapid, inexpensive point-of-care testing, while also noting that commercialization still depends on stable conductive materials, manufacturability, and regulatory translation. A separate veterinary-focused review has similarly described electrochemical and nanomaterial-enabled platforms as attractive for farm animal and livestock diagnostics because they can support portable, low-cost testing closer to the site of care. (pubs.rsc.org)
iGii’s own product materials frame Gii-Sens as an answer to that commercialization gap. The company says the platform is manufactured using only a substrate and electricity, without inks, binders, or additives, creating a porous 3D carbon nanostructure with a large electrochemically active surface area. According to iGii, that design helps reduce surface fouling and maintain reliable performance in complex matrices including blood, urine, and milk, while also supporting reel-to-sheet and reel-to-reel manufacturing formats. The company also markets an assay development service intended to take partners from screening through early validation and toward commercialization. (igii.uk)
The ADLM announcement itself is short on new validation data, but it does clarify what iGii wants potential partners to see: a materials platform, research electrodes for assay development, microheaters for molecular diagnostics, and examples of integration into customer products. That suggests the company is positioning itself less as a finished-test manufacturer and more as an enabling technology supplier for developers building electrochemical or thermally driven diagnostic systems. That’s consistent with iGii’s earlier messaging. In January 2024, the company said Gii-Sens had been shown to match or outperform traditional electrode materials, including gold, at lower cost, and that it was pursuing healthcare relationships in the United Kingdom, United States, European Union, Australia, and New Zealand. (newswise.com)
Independent literature broadly supports the strategic logic, even if it doesn’t validate iGii specifically. Reviews in the field describe carbon nanomaterials as well suited to electrochemical biosensing because of their electrical, chemical, structural, and mechanical properties, and note their potential role in portable and decentralized diagnostics. Industry discussion is also increasingly focused on the harder part: not proving a concept in the lab, but building something that can be manufactured reproducibly, integrated into workflows, and brought through regulatory review. An IEEE BioSensors 2026 panel description, for example, highlights commercialization, regulation, and manufacturing as central hurdles for electrochemical point-of-care biosensors. (pubs.rsc.org)
Why it matters: For veterinary professionals, the practical significance is downstream but real. If companies can replace costly or harder-to-scale electrode materials with carbon-based platforms that still perform well in messy biological samples, that could improve the economics and availability of near-patient tests in companion animal and livestock care. Faster assay development and more manufacturable sensor formats could matter for everything from infectious disease screening and herd surveillance to metabolic monitoring and in-clinic molecular testing. The caveat is that platform claims do not automatically translate into validated veterinary products, so the real signal will be partner announcements, performance data, and evidence that assays hold up outside controlled development settings. (igii.uk)
What to watch: After ADLM 2026, watch for named collaborations, poster or study data, and any movement from research-use positioning toward regulated diagnostic deployment. For veterinary teams, the key question isn’t whether carbon nanomaterials are interesting, but whether they can help deliver reliable, scalable point-of-care tests that fit real clinical and field workflows. (newswise.com)